Serum YKL-40 and Colorectal Cancer
Author Information
Author(s): Cintin C, Johansen J S, Christensen I J, Price P A, Sørensen S, Nielsen H J
Primary Institution: University of Copenhagen, Hvidovre Hospital
Hypothesis
The study evaluates the relationship between serum YKL-40 levels and survival in colorectal cancer patients.
Conclusion
High serum YKL-40 levels are associated with shorter survival in colorectal cancer patients.
Supporting Evidence
- High serum YKL-40 has been linked to short survival in breast cancer patients.
- In this study, 340 out of 603 patients died during the follow-up period.
- Patients with high YKL-40 levels had a hazard ratio of 1.7 for shorter survival.
- Multivariate analysis showed high YKL-40 as an independent prognostic factor.
Takeaway
If you have high levels of a protein called YKL-40 in your blood, it might mean you won't live as long after surgery for colon cancer.
Methodology
Serum YKL-40 was measured in preoperative sera from patients, and survival was tracked over a median follow-up of 61 months.
Participant Demographics
Patients with colorectal cancer, with varying Dukes' stages.
Statistical Information
P-Value
P < 0.0001; P = 0.007
Confidence Interval
95% CI: 1.3–2.1; 95% CI: 1.1–1.8
Statistical Significance
p<0.0001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website